Work

Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal

Year: 2026

Type: article

Abstract: This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.

Source: JAMA Health Forum

DOI: 10.1001/jamahealthforum.2026.0680

Authors: Zeid S El-Kilani, Sanika Kulkarni, Joseph F. Levy

Institutions: Carnegie Mellon University, Johns Hopkins University

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,000

OpenAlex ID: W7160651446

FWCI:

Cites: 2

Cited by:

Related to: